Ray Gilmartin faces a dilemma. His institution's credibility has been damaged by the recent withdrawal of Vioxx, a multi-billion dollar drug. Additionally, the withdrawal of Vioxx would entail that Merck would fail to meet analysts' earnings expectations for year 2005 unless the funds R&D cuts on Productivity and morale might hurt in Merck labs.
PUBLICATION DATE: September 24, 2010 PRODUCT #: 611027-PDF-ENG
This is just an excerpt. This case is about TECHNOLOGY & OPERATIONS
Related Case Solutions & Analyses:
Rio Tinto Iron Ore: Challenges of Globalization in the Mining Industry
Halton Recycling Ltd.
Westin Hotels and Resorts: Operations of a Lifestyle Experience
Fritidsresor Under Pressure (A): The First 10 Hours
Wal-Mart Stores: Everyday Low Prices in China
Lulu.com
Tombow Pencil Co. Ltd.
Online Piracy: Jaywalking or Theft?
The TSMC Way: Meeting Customer Needs at Taiwan Semiconductor Manufacturing Co.
Ferrero Group: Securing Supply for Hazelnuts
